NO314307B1 - Nye 2-aminoindanforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholder dem - Google Patents
Nye 2-aminoindanforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholder dem Download PDFInfo
- Publication number
- NO314307B1 NO314307B1 NO19980803A NO980803A NO314307B1 NO 314307 B1 NO314307 B1 NO 314307B1 NO 19980803 A NO19980803 A NO 19980803A NO 980803 A NO980803 A NO 980803A NO 314307 B1 NO314307 B1 NO 314307B1
- Authority
- NO
- Norway
- Prior art keywords
- piperidine
- amino
- fumarate
- dihydro
- benzodioxin
- Prior art date
Links
- LMHHFZAXSANGGM-UHFFFAOYSA-N 2-aminoindane Chemical class C1=CC=C2CC(N)CC2=C1 LMHHFZAXSANGGM-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 238000000034 method Methods 0.000 title claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 46
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 125000005843 halogen group Chemical group 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 230000003287 optical effect Effects 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 3
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 74
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 65
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 10
- -1 trifluoromethyl- Chemical group 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims description 6
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 230000002295 serotoninergic effect Effects 0.000 claims description 5
- 239000012279 sodium borohydride Substances 0.000 claims description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000006268 reductive amination reaction Methods 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- LZLFUVVRGYHCMN-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-8-yl)-n-(2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound C1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=CC=C2C1 LZLFUVVRGYHCMN-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- BUVGYTAHPWYIHL-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-(5-methyl-2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=C(C)C=C2C1 BUVGYTAHPWYIHL-UHFFFAOYSA-N 0.000 claims description 2
- DIFUSAAJEXBWDZ-UHFFFAOYSA-N 1-(2,3-dihydro-1-benzofuran-7-yl)-n-(5-fluoro-2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound C1C2=CC(F)=CC=C2CC1NC(CC1)CCN1C1=CC=CC2=C1OCC2 DIFUSAAJEXBWDZ-UHFFFAOYSA-N 0.000 claims description 2
- RJDOVNUUXOKEOU-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-8-yl)-n-(5-fluoro-2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound C1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=C(F)C=C2C1 RJDOVNUUXOKEOU-UHFFFAOYSA-N 0.000 claims description 2
- GYRHSRZYIFQPEU-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-8-yl)-n-(5-methoxy-2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound C1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=C(OC)C=C2C1 GYRHSRZYIFQPEU-UHFFFAOYSA-N 0.000 claims description 2
- RCBHFTIWVWXGBL-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-8-yl)-n-(6,7-dihydro-5h-cyclopenta[f][1,3]benzodioxol-6-yl)piperidin-4-amine Chemical compound C1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC(C=C2OCOC2=C2)=C2C1 RCBHFTIWVWXGBL-UHFFFAOYSA-N 0.000 claims description 2
- VPVYSMHKTMCEEJ-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-8-yl)-n-[5-(1,2,4-triazol-4-yl)-2,3-dihydro-1h-inden-2-yl]piperidin-4-amine Chemical compound C=1C=C2CC(NC3CCN(CC3)C=3C=4OCCCC=4C=CC=3)CC2=CC=1N1C=NN=C1 VPVYSMHKTMCEEJ-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 2
- KGSJYPZELGLEKH-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-2-yl)-1-(3,4-dihydro-2h-thiochromen-8-yl)piperidin-4-amine Chemical compound C1CCSC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=CC=C2C1 KGSJYPZELGLEKH-UHFFFAOYSA-N 0.000 claims description 2
- MJVBMEVMDBMTPD-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-2-yl)-1-(6-fluoro-3,4-dihydro-2h-chromen-8-yl)piperidin-4-amine Chemical compound C1C2=CC=CC=C2CC1NC(CC1)CCN1C1=CC(F)=CC2=C1OCCC2 MJVBMEVMDBMTPD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- KQNGVKMDIANDHU-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-(2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=CC=C2C1 KQNGVKMDIANDHU-UHFFFAOYSA-N 0.000 claims 2
- PEEYUYFAZNTREO-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-(4,7-dimethoxy-2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC(C(OC)=CC=C2OC)=C2C1 PEEYUYFAZNTREO-UHFFFAOYSA-N 0.000 claims 1
- RIFGFCMZLBEHKB-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-(5,6-dimethyl-2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC(C=C(C(=C2)C)C)=C2C1 RIFGFCMZLBEHKB-UHFFFAOYSA-N 0.000 claims 1
- UNUJRVRWPYDMAF-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-(5-fluoro-2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=C(F)C=C2C1 UNUJRVRWPYDMAF-UHFFFAOYSA-N 0.000 claims 1
- CAHPKHAYVYBJAS-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-(5-methoxy-2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=C(OC)C=C2C1 CAHPKHAYVYBJAS-UHFFFAOYSA-N 0.000 claims 1
- IMVGGCKYFHDIGP-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-(5-nitro-2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=C([N+](=O)[O-])C=C2C1 IMVGGCKYFHDIGP-UHFFFAOYSA-N 0.000 claims 1
- MXNPZIASPIXENL-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-(6,7-dihydro-5h-cyclopenta[f][1,3]benzodioxol-6-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC(C=C2OCOC2=C2)=C2C1 MXNPZIASPIXENL-UHFFFAOYSA-N 0.000 claims 1
- HPEIHRXXYHODTL-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-[5-(trifluoromethyl)-2,3-dihydro-1h-inden-2-yl]piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=C(C(F)(F)F)C=C2C1 HPEIHRXXYHODTL-UHFFFAOYSA-N 0.000 claims 1
- FKSPATRLBQPGIQ-UHFFFAOYSA-N 2-[[1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-yl]amino]-2,3-dihydro-1h-inden-5-ol Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=C(O)C=C2C1 FKSPATRLBQPGIQ-UHFFFAOYSA-N 0.000 claims 1
- JNWIJVIWQUVKQS-UHFFFAOYSA-N 2-[[1-(3,4-dihydro-2h-chromen-8-yl)piperidin-4-yl]amino]-2,3-dihydro-1h-inden-5-ol Chemical compound C1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=C(O)C=C2C1 JNWIJVIWQUVKQS-UHFFFAOYSA-N 0.000 claims 1
- OGFMFRWOQWESLG-UHFFFAOYSA-N 8-[4-(6,7-dihydro-5h-cyclopenta[f][1,3]benzodioxol-6-ylamino)piperidin-1-yl]-3,4-dihydro-2h-chromen-4-ol Chemical compound C1C2=CC=3OCOC=3C=C2CC1NC(CC1)CCN1C1=CC=CC2=C1OCCC2O OGFMFRWOQWESLG-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 claims 1
- FCQFWLMWZZXDGR-UHFFFAOYSA-N n-(5-chloro-2,3-dihydro-1h-inden-2-yl)-1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NC1CC2=CC=C(Cl)C=C2C1 FCQFWLMWZZXDGR-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 239000000047 product Substances 0.000 description 145
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000155 melt Substances 0.000 description 19
- 238000010992 reflux Methods 0.000 description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 239000003480 eluent Substances 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 238000001704 evaporation Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- BFKBHPVGDFWCCR-UHFFFAOYSA-N 5,7-dihydrocyclopenta[f][1,3]benzodioxol-6-one Chemical compound C1=C2CC(=O)CC2=CC2=C1OCO2 BFKBHPVGDFWCCR-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 229940076279 serotonin Drugs 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- OFVNPOZRBPSFSH-UHFFFAOYSA-N 5-fluoro-1,3-dihydroinden-2-one Chemical compound FC1=CC=C2CC(=O)CC2=C1 OFVNPOZRBPSFSH-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- XAUMPAFHUJRROX-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-8-yl)piperidin-4-one Chemical compound C1CC(=O)CCN1C1=CC=CC2=C1OCCC2 XAUMPAFHUJRROX-UHFFFAOYSA-N 0.000 description 5
- 241000700198 Cavia Species 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000001530 fumaric acid Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- XEHNLVMHWYPNEQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-2-amine;hydron;chloride Chemical compound Cl.C1=CC=C2CC(N)CC2=C1 XEHNLVMHWYPNEQ-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 239000007868 Raney catalyst Substances 0.000 description 4
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000002287 radioligand Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- QUYCPYFNAZEWOT-UHFFFAOYSA-N 2,3-dihydro-1h-inden-2-yl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CC2=CC=CC=C2C1 QUYCPYFNAZEWOT-UHFFFAOYSA-N 0.000 description 3
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 210000005153 frontal cortex Anatomy 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- WNUMFWKPEKSQJO-UHFFFAOYSA-N 1,5-dibromopentan-3-amine;hydrobromide Chemical compound Br.BrCCC(N)CCBr WNUMFWKPEKSQJO-UHFFFAOYSA-N 0.000 description 2
- YSGMPRKCWCLCPG-UHFFFAOYSA-N 1-(1-benzofuran-7-yl)piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC2=C1OC=C2 YSGMPRKCWCLCPG-UHFFFAOYSA-N 0.000 description 2
- VEBPRSTYWWNWEF-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC2=C1OCCO2 VEBPRSTYWWNWEF-UHFFFAOYSA-N 0.000 description 2
- FGLFTGVMXLHTTP-UHFFFAOYSA-N 1-(2,3-dihydro-1-benzofuran-7-yl)piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC2=C1OCC2 FGLFTGVMXLHTTP-UHFFFAOYSA-N 0.000 description 2
- RBNZLNCNRVIFIJ-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-8-yl)piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC2=C1OCCC2 RBNZLNCNRVIFIJ-UHFFFAOYSA-N 0.000 description 2
- KPLZUBANTJJRAN-UHFFFAOYSA-N 1-(6-fluoro-3,4-dihydro-2h-chromen-8-yl)piperidin-4-one Chemical compound C=1C(F)=CC=2CCCOC=2C=1N1CCC(=O)CC1 KPLZUBANTJJRAN-UHFFFAOYSA-N 0.000 description 2
- DMLRSJNZORFCBD-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-5-amine Chemical compound O1CCOC2=C1C=CC=C2N DMLRSJNZORFCBD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- CEYJHHLKVOTTOC-UHFFFAOYSA-N 5-methoxy-1,3-dihydroinden-2-one Chemical compound COC1=CC=C2CC(=O)CC2=C1 CEYJHHLKVOTTOC-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- 102000007527 Autoreceptors Human genes 0.000 description 2
- 108010071131 Autoreceptors Proteins 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 101150050738 HTR1B gene Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 231100000870 cognitive problem Toxicity 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- UMJJFEIKYGFCAT-UHFFFAOYSA-N indan-2-one Chemical compound C1=CC=C2CC(=O)CC2=C1 UMJJFEIKYGFCAT-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- YKUCHDXIBAQWSF-UHFFFAOYSA-N methyl 3-hydroxybenzoate Chemical compound COC(=O)C1=CC=CC(O)=C1 YKUCHDXIBAQWSF-UHFFFAOYSA-N 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 229960001779 pargyline Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- FMMVFODZYMQGMD-UHFFFAOYSA-N (8-amino-3,4-dihydro-2h-chromen-4-yl) acetate Chemical compound C1=CC=C2C(OC(=O)C)CCOC2=C1N FMMVFODZYMQGMD-UHFFFAOYSA-N 0.000 description 1
- BKYMPRVRXYMNMF-UHFFFAOYSA-N (8-nitro-3,4-dihydro-2h-chromen-4-yl) acetate Chemical compound C1=CC=C([N+]([O-])=O)C2=C1C(OC(=O)C)CCO2 BKYMPRVRXYMNMF-UHFFFAOYSA-N 0.000 description 1
- IIMOAOXQJWKTRB-UHFFFAOYSA-N 1-(1-benzofuran-7-yl)-n-(5-fluoro-2,3-dihydro-1h-inden-2-yl)piperidin-4-amine Chemical compound C1C2=CC(F)=CC=C2CC1NC(CC1)CCN1C1=CC=CC2=C1OC=C2 IIMOAOXQJWKTRB-UHFFFAOYSA-N 0.000 description 1
- HINFLVUJAOOGAQ-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-methylpiperidin-4-amine Chemical compound C1CC(C)(N)CCN1C1=CC=CC2=C1OCCO2 HINFLVUJAOOGAQ-UHFFFAOYSA-N 0.000 description 1
- WSRFCQBXRQWUMB-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-methylpiperidin-4-ol Chemical compound C1CC(C)(O)CCN1C1=CC=CC2=C1OCCO2 WSRFCQBXRQWUMB-UHFFFAOYSA-N 0.000 description 1
- IKZLCMYKNSOJJR-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-(2,3-dihydro-1h-inden-2-yl)-4-methylpiperidin-4-amine Chemical compound C1C2=CC=CC=C2CC1NC1(C)CCN(C=2C=3OCCOC=3C=CC=2)CC1 IKZLCMYKNSOJJR-UHFFFAOYSA-N 0.000 description 1
- FDTWYJVDDIUWSE-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-methylpiperidin-4-amine Chemical compound C1CC(NC)CCN1C1=CC=CC2=C1OCCO2 FDTWYJVDDIUWSE-UHFFFAOYSA-N 0.000 description 1
- LDCFHPZNOVDJQJ-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)pyrrolidin-3-ol Chemical compound C1C(O)CCN1C1=CC=CC2=C1OCCO2 LDCFHPZNOVDJQJ-UHFFFAOYSA-N 0.000 description 1
- MLMJCEDDSSAQQB-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)pyrrolidin-3-one Chemical compound C1C(=O)CCN1C1=CC=CC2=C1OCCO2 MLMJCEDDSSAQQB-UHFFFAOYSA-N 0.000 description 1
- LRCUSZIOJJZCBJ-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzoxathiin-5-yl)piperidin-4-ol Chemical compound C1CC(O)CCN1C1=CC=CC2=C1SCCO2 LRCUSZIOJJZCBJ-UHFFFAOYSA-N 0.000 description 1
- FHNFZJMSSFRVBG-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzoxathiin-5-yl)piperidin-4-one Chemical compound C1CC(=O)CCN1C1=CC=CC2=C1SCCO2 FHNFZJMSSFRVBG-UHFFFAOYSA-N 0.000 description 1
- NPAFKAHOMJBLEV-UHFFFAOYSA-N 1-(3,4-dihydro-2h-thiochromen-8-yl)piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC2=C1SCCC2 NPAFKAHOMJBLEV-UHFFFAOYSA-N 0.000 description 1
- YYWJHOJMCOIVNS-UHFFFAOYSA-N 1-benzofuran-7-amine Chemical compound NC1=CC=CC2=C1OC=C2 YYWJHOJMCOIVNS-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- JAEDEGBDHMQTRE-UHFFFAOYSA-N 2,3-dihydro-1,4-benzoxathiin-5-amine Chemical compound O1CCSC2=C1C=CC=C2N JAEDEGBDHMQTRE-UHFFFAOYSA-N 0.000 description 1
- XKTNBHGAWMIJDU-UHFFFAOYSA-N 2,3-dihydro-1,4-benzoxathiine-5-carboxylic acid Chemical compound O1CCSC2=C1C=CC=C2C(=O)O XKTNBHGAWMIJDU-UHFFFAOYSA-N 0.000 description 1
- UHHZGSLXPQGPJL-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-7-amine Chemical compound NC1=CC=CC2=C1OCC2 UHHZGSLXPQGPJL-UHFFFAOYSA-N 0.000 description 1
- ILXAZFRYAXWHNA-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-8-amine Chemical compound C1CCOC2=C1C=CC=C2N ILXAZFRYAXWHNA-UHFFFAOYSA-N 0.000 description 1
- XVLIVDNUXFJPLY-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromen-8-amine Chemical compound C1CCSC2=C1C=CC=C2N XVLIVDNUXFJPLY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YUMCNWYMGKEVMD-UHFFFAOYSA-N 3h-cyclopenta[f][2,1,3]benzoxadiazol-6-amine;hydrochloride Chemical compound Cl.C=1C2=NONC2=CC2=CC(N)=CC2=1 YUMCNWYMGKEVMD-UHFFFAOYSA-N 0.000 description 1
- LRHXSJHVFJSPBT-UHFFFAOYSA-N 4,7-dimethoxy-1,3-dihydroinden-2-one Chemical compound COC1=CC=C(OC)C2=C1CC(=O)C2 LRHXSJHVFJSPBT-UHFFFAOYSA-N 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- JHQLFEYMQZTCOZ-UHFFFAOYSA-N 5,6-dimethoxy-1,3-dihydroinden-2-one Chemical compound C1=C(OC)C(OC)=CC2=C1CC(=O)C2 JHQLFEYMQZTCOZ-UHFFFAOYSA-N 0.000 description 1
- VGOZNIPJKGIMBZ-UHFFFAOYSA-N 5,6-dimethyl-1,3-dihydroinden-2-one Chemical compound C1=C(C)C(C)=CC2=C1CC(=O)C2 VGOZNIPJKGIMBZ-UHFFFAOYSA-N 0.000 description 1
- MEQDVZODCXEPCT-UHFFFAOYSA-N 5-(1,2,4-triazol-4-yl)-2,3-dihydro-1h-inden-2-amine Chemical compound C1=C2CC(N)CC2=CC=C1N1C=NN=C1 MEQDVZODCXEPCT-UHFFFAOYSA-N 0.000 description 1
- FHCVLLGIROLJTL-UHFFFAOYSA-N 5-(1,2,4-triazol-4-yl)-2,3-dihydro-1h-inden-2-amine;hydrochloride Chemical compound Cl.C1=C2CC(N)CC2=CC=C1N1C=NN=C1 FHCVLLGIROLJTL-UHFFFAOYSA-N 0.000 description 1
- AKNWXTBHGMGKRM-UHFFFAOYSA-N 5-(trifluoromethyl)-1,3-dihydroinden-2-one Chemical compound FC(F)(F)C1=CC=C2CC(=O)CC2=C1 AKNWXTBHGMGKRM-UHFFFAOYSA-N 0.000 description 1
- MMMPPHUZDOMQDG-UHFFFAOYSA-N 5-chloro-1,3-dihydroinden-2-one Chemical compound ClC1=CC=C2CC(=O)CC2=C1 MMMPPHUZDOMQDG-UHFFFAOYSA-N 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
- QLOAMIGYZXLFKF-UHFFFAOYSA-N 5-methyl-1,3-dihydroinden-2-one Chemical compound CC1=CC=C2CC(=O)CC2=C1 QLOAMIGYZXLFKF-UHFFFAOYSA-N 0.000 description 1
- MDRSLNMEVGJERF-UHFFFAOYSA-N 5-nitro-2,3-dihydro-1h-inden-2-amine Chemical compound C1=C([N+]([O-])=O)C=C2CC(N)CC2=C1 MDRSLNMEVGJERF-UHFFFAOYSA-N 0.000 description 1
- FFGLVSGGGJOMQY-UHFFFAOYSA-N 5-nitro-2,3-dihydro-1h-inden-2-amine;hydrochloride Chemical compound Cl.C1=C([N+]([O-])=O)C=C2CC(N)CC2=C1 FFGLVSGGGJOMQY-UHFFFAOYSA-N 0.000 description 1
- AEICTTXLAITIQJ-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromen-8-amine Chemical compound C1CCOC2=C1C=C(F)C=C2N AEICTTXLAITIQJ-UHFFFAOYSA-N 0.000 description 1
- AADYIFLRRCYLRF-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromene Chemical compound O1CCCC2=CC(F)=CC=C21 AADYIFLRRCYLRF-UHFFFAOYSA-N 0.000 description 1
- RSVLOWLCSDVHKN-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromene-8-carbaldehyde Chemical compound C1CCOC2=C1C=C(F)C=C2C=O RSVLOWLCSDVHKN-UHFFFAOYSA-N 0.000 description 1
- DCDTYZGACGGIHH-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromene-8-carboxylic acid Chemical compound C1CCOC2=C1C=C(F)C=C2C(=O)O DCDTYZGACGGIHH-UHFFFAOYSA-N 0.000 description 1
- DEJQDCVTJHJEMP-UHFFFAOYSA-N 8-chloro-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine Chemical compound O1CCOC2=C1N=CC=C2Cl DEJQDCVTJHJEMP-UHFFFAOYSA-N 0.000 description 1
- KJEIUABTKUEPLY-UHFFFAOYSA-N 8-nitro-3,4-dihydro-2h-chromen-4-ol Chemical compound C1=CC=C([N+]([O-])=O)C2=C1C(O)CCO2 KJEIUABTKUEPLY-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 1
- 101710114597 Sodium-dependent serotonin transporter Proteins 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- KYIJWVJKDWCRBL-UHFFFAOYSA-N benzyl n-(6-fluoro-3,4-dihydro-2h-chromen-8-yl)carbamate Chemical compound C=1C(F)=CC=2CCCOC=2C=1NC(=O)OCC1=CC=CC=C1 KYIJWVJKDWCRBL-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- WVSDPFHWSQWSSC-UHFFFAOYSA-N ethyl n-[1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-yl]carbamate Chemical compound C1CC(NC(=O)OCC)CCN1C1=CC=CC2=C1OCCO2 WVSDPFHWSQWSSC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- OBZXAHPZUFVVRI-UHFFFAOYSA-N methyl 2,3-dihydro-1,4-benzoxathiine-5-carboxylate Chemical compound O1CCSC2=C1C=CC=C2C(=O)OC OBZXAHPZUFVVRI-UHFFFAOYSA-N 0.000 description 1
- 229940120152 methyl 3-hydroxybenzoate Drugs 0.000 description 1
- OXQRLBFDJMSRMM-UHFFFAOYSA-N methyl 3-hydroxycyclohexane-1-carboxylate Chemical compound COC(=O)C1CCCC(O)C1 OXQRLBFDJMSRMM-UHFFFAOYSA-N 0.000 description 1
- MAEFSJWFUPHVPY-UHFFFAOYSA-N methyl 3-oxocyclohexane-1-carboxylate Chemical compound COC(=O)C1CCCC(=O)C1 MAEFSJWFUPHVPY-UHFFFAOYSA-N 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- MIJBHSBEKPGHDQ-UHFFFAOYSA-N n-(3h-cyclopenta[f][2,1,3]benzoxadiazol-6-yl)acetamide Chemical compound C=1C2=NONC2=CC2=CC(NC(=O)C)=CC2=1 MIJBHSBEKPGHDQ-UHFFFAOYSA-N 0.000 description 1
- IBQMBDAOKKRUDX-UHFFFAOYSA-N n-(5-amino-2,3-dihydro-1h-inden-2-yl)acetamide Chemical compound C1=C(N)C=C2CC(NC(=O)C)CC2=C1 IBQMBDAOKKRUDX-UHFFFAOYSA-N 0.000 description 1
- HMTMYYKVAGYEEW-UHFFFAOYSA-N n-(5-amino-6-nitro-2,3-dihydro-1h-inden-2-yl)acetamide Chemical compound NC1=C([N+]([O-])=O)C=C2CC(NC(=O)C)CC2=C1 HMTMYYKVAGYEEW-UHFFFAOYSA-N 0.000 description 1
- COGGGWRHZQTITF-UHFFFAOYSA-N n-(oxan-4-ylidene)hydroxylamine Chemical compound ON=C1CCOCC1 COGGGWRHZQTITF-UHFFFAOYSA-N 0.000 description 1
- DLBUCYGKKXLHOG-UHFFFAOYSA-N n-[1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-methylpiperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)(C)CCN1C1=CC=CC2=C1OCCO2 DLBUCYGKKXLHOG-UHFFFAOYSA-N 0.000 description 1
- OCRMQBFUELEDCA-UHFFFAOYSA-N n-[1-(3,4-dihydro-2h-chromen-8-yl)piperidin-4-ylidene]hydroxylamine Chemical compound C1CC(=NO)CCN1C1=CC=CC2=C1OCCC2 OCRMQBFUELEDCA-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- KWZSCXIYGVEHOB-UHFFFAOYSA-N oxan-4-amine;hydrochloride Chemical compound [Cl-].[NH3+]C1CCOCC1 KWZSCXIYGVEHOB-UHFFFAOYSA-N 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical group NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- AIMUHNZKNFEZSN-UHFFFAOYSA-M sodium;decane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCS([O-])(=O)=O AIMUHNZKNFEZSN-UHFFFAOYSA-M 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZCDQUMICDAFZJZ-UHFFFAOYSA-N tert-butyl n-(3,4-dihydro-2h-thiochromen-8-yl)carbamate Chemical compound C1CCSC2=C1C=CC=C2NC(=O)OC(C)(C)C ZCDQUMICDAFZJZ-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9702360A FR2760014B1 (fr) | 1997-02-27 | 1997-02-27 | Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO980803D0 NO980803D0 (no) | 1998-02-26 |
| NO980803L NO980803L (no) | 1998-08-28 |
| NO314307B1 true NO314307B1 (no) | 2003-03-03 |
Family
ID=9504253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19980803A NO314307B1 (no) | 1997-02-27 | 1998-02-26 | Nye 2-aminoindanforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholder dem |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5968954A (zh) |
| EP (1) | EP0861837B1 (zh) |
| JP (1) | JPH10237071A (zh) |
| CN (1) | CN1090627C (zh) |
| AT (1) | ATE265451T1 (zh) |
| AU (1) | AU725756B2 (zh) |
| BR (1) | BR9800763A (zh) |
| CA (1) | CA2231025C (zh) |
| DE (1) | DE69823411T2 (zh) |
| DK (1) | DK0861837T3 (zh) |
| ES (1) | ES2219853T3 (zh) |
| FR (1) | FR2760014B1 (zh) |
| HK (1) | HK1014945A1 (zh) |
| HU (1) | HU224312B1 (zh) |
| NO (1) | NO314307B1 (zh) |
| NZ (1) | NZ329853A (zh) |
| PL (1) | PL190240B1 (zh) |
| PT (1) | PT861837E (zh) |
| ZA (1) | ZA981680B (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI274750B (en) | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
| SE0103650D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic heterocyclic compounds |
| KR20080079341A (ko) * | 2001-01-16 | 2008-08-29 | 아스트라제네카 아베 | 치료용 헤테로시클릭 화합물 |
| ATE424825T1 (de) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
| JP2005343790A (ja) * | 2002-05-31 | 2005-12-15 | Ajinomoto Co Inc | カルシウムチャネル拮抗薬を含有する医薬組成物 |
| US20050165025A1 (en) * | 2004-01-22 | 2005-07-28 | Recordati Ireland Ltd. | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists |
| WO2006062063A1 (ja) * | 2004-12-08 | 2006-06-15 | Astellas Pharma Inc. | ピペリジン誘導体及びその製造法 |
| UY29892A1 (es) * | 2005-11-04 | 2007-06-29 | Astrazeneca Ab | Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9318431D0 (en) * | 1993-09-06 | 1993-10-20 | Boots Co Plc | Therapeutic agents |
| FR2734819B1 (fr) * | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
-
1997
- 1997-02-27 FR FR9702360A patent/FR2760014B1/fr not_active Expired - Fee Related
-
1998
- 1998-02-24 PL PL98324982A patent/PL190240B1/pl not_active IP Right Cessation
- 1998-02-25 BR BR9800763-7A patent/BR9800763A/pt not_active Application Discontinuation
- 1998-02-25 JP JP10042716A patent/JPH10237071A/ja active Pending
- 1998-02-26 CA CA002231025A patent/CA2231025C/fr not_active Expired - Fee Related
- 1998-02-26 HU HU9800422A patent/HU224312B1/hu not_active IP Right Cessation
- 1998-02-26 CN CN98107709A patent/CN1090627C/zh not_active Expired - Fee Related
- 1998-02-26 NO NO19980803A patent/NO314307B1/no unknown
- 1998-02-26 US US09/031,490 patent/US5968954A/en not_active Expired - Fee Related
- 1998-02-26 NZ NZ329853A patent/NZ329853A/xx unknown
- 1998-02-27 DE DE69823411T patent/DE69823411T2/de not_active Expired - Fee Related
- 1998-02-27 ZA ZA981680A patent/ZA981680B/xx unknown
- 1998-02-27 PT PT98400469T patent/PT861837E/pt unknown
- 1998-02-27 ES ES98400469T patent/ES2219853T3/es not_active Expired - Lifetime
- 1998-02-27 AT AT98400469T patent/ATE265451T1/de not_active IP Right Cessation
- 1998-02-27 AU AU56359/98A patent/AU725756B2/en not_active Ceased
- 1998-02-27 DK DK98400469T patent/DK0861837T3/da active
- 1998-02-27 EP EP98400469A patent/EP0861837B1/fr not_active Expired - Lifetime
-
1999
- 1999-01-07 HK HK99100037A patent/HK1014945A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HU224312B1 (hu) | 2005-07-28 |
| AU5635998A (en) | 1998-09-03 |
| PL190240B1 (pl) | 2005-11-30 |
| DE69823411T2 (de) | 2005-02-17 |
| DK0861837T3 (da) | 2004-08-16 |
| CN1194983A (zh) | 1998-10-07 |
| HU9800422D0 (en) | 1998-04-28 |
| NO980803D0 (no) | 1998-02-26 |
| ATE265451T1 (de) | 2004-05-15 |
| PL324982A1 (en) | 1998-08-31 |
| HUP9800422A1 (hu) | 1999-12-28 |
| ES2219853T3 (es) | 2004-12-01 |
| US5968954A (en) | 1999-10-19 |
| AU725756B2 (en) | 2000-10-19 |
| EP0861837A1 (fr) | 1998-09-02 |
| ZA981680B (en) | 1998-09-04 |
| CA2231025A1 (fr) | 1998-08-27 |
| CN1090627C (zh) | 2002-09-11 |
| CA2231025C (fr) | 2003-09-16 |
| HK1014945A1 (en) | 1999-10-08 |
| EP0861837B1 (fr) | 2004-04-28 |
| NO980803L (no) | 1998-08-28 |
| NZ329853A (en) | 1999-01-28 |
| JPH10237071A (ja) | 1998-09-08 |
| FR2760014B1 (fr) | 1999-04-09 |
| DE69823411D1 (de) | 2004-06-03 |
| PT861837E (pt) | 2004-07-30 |
| FR2760014A1 (fr) | 1998-08-28 |
| BR9800763A (pt) | 1999-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU731018B2 (en) | New N-aryl piperidine compounds, a process for their preparation and pharmaceutical compositions containing them | |
| CA2253429C (en) | 2,4-diaminopyrimidine derivates as dopamine d4 receptor antagonists | |
| NO314185B1 (no) | Nye alkoksyarylforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem | |
| AU2010311321B2 (en) | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors | |
| KR101663635B1 (ko) | 크로몬 유도체, 그 제조방법 및 그들의 치료 분야 | |
| JP2017503837A (ja) | ピリジン類及びピリミジン類並びにその使用 | |
| CZ20012657A3 (cs) | Piperidinové, tetrahydropyridinové a piperazinové deriváty | |
| JP6466602B2 (ja) | ムスカリンｍ１受容体ポジティブアロステリックモジュレーター | |
| US20080318941A1 (en) | 4' substituted compounds having 5-ht6 receptor affinity | |
| NO314307B1 (no) | Nye 2-aminoindanforbindelser, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholder dem | |
| CA2316388C (en) | Tetrahydrobenzindole derivative | |
| RU2480462C2 (ru) | Производные пиридина, используемые в качестве быстро диссоциирующихся антагонистов допаминовых рецепторов 2 | |
| JP2003509432A (ja) | Ｄ４拮抗剤として有用なチエノイソキサゾリル−およびチエニルピラゾリル−フェノキシ置換プロピル誘導体 | |
| NO313415B1 (no) | Oksazolidiner, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstilling derav,forbindelsene 5-HT2A-antagonister, samt anvendelse avforbindelsene til fremstilling av legemidler | |
| US6153625A (en) | Indan-1-ol compounds | |
| EP1613594B1 (en) | 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors | |
| NO316693B1 (no) | Nye indanolforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| JP2001114778A (ja) | テトラヒドロキナゾリン−２，４−ジオンおよびそれらの治療用途 | |
| Peglion et al. | 2-aminoindan compounds as 5HT 1B antagonists | |
| PL240473B1 (pl) | N-6(4-arylopiperazyn-1-ylo)heksylowe pochodne cyklicznych 1,8-naftylo / tetrahydrochinolino imidów / amidów / sulfonamidów oraz sposób ich otrzymywania |